Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 20/20 | 0.64 |
| ▸ | MMP2 | P08253 | 19/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 17/20 | 0.64 |
| ▸ | MMP9 | P14780 | 12/20 | 0.61 |
| ▸ | MMP3 | P08254 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528036 | 0.88 | ADAM10 (0.60) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1366806 | 0.88 | ADAM10 (0.60) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL3648643 | 0.85 | ADAM10 (0.79) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL4638822 | 0.85 | ADAM10 (0.79) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1367687 | 0.84 | ADAM10 (0.58) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1364457 | 0.84 | ADAM10 (0.61) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1364256 | 0.84 | ADAM10 (0.61) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1364063 | 0.82 | ADAM10 (0.59) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1365531 | 0.82 | ADAM10 (0.59) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL1365597 | 0.81 | ADAM10 (0.66) | ADAM10MMP2ERBB2MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187530-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION (US) | 2014-07-03 | — | — | US | claimed |
| US-8088737-B2 | Treating a cancer, in particular breast cancer, that overexpresses Her-2 by administering an ADAM inhibitor; novel variants of ADAM15 and ADAM15; synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds | INCYTE CORPORATION (US) | 2012-01-03 | — | — | US | claimed |
| US-8039471-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2011-10-18 | — | — | US | claimed |
| US-7723349-B2 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION (US) | 2010-05-25 | — | — | US | claimed |
| US-20070280943-A1 | SHEDDASE INHIBITORS COMBINED WITH CD30-BINDING IMMUNOTHERAPEUTICS FOR THE TREATMENT OF CD30 POSITIVE DISEASES | INCYTE CORPORATION | 2007-12-06 | — | — | US | claimed |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION | 2004-12-23 | — | — | US | claimed |
| US-9403775-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-20140187530-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20110288068-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION | 2011-11-24 | — | — | US | disclosed |
| US-8039471-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-7910108-B2 | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases | INCYTE CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-7723349-B2 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070280943-A1 | SHEDDASE INHIBITORS COMBINED WITH CD30-BINDING IMMUNOTHERAPEUTICS FOR THE TREATMENT OF CD30 POSITIVE DISEASES | INCYTE CORPORATION | 2007-12-06 | — | — | US | disclosed |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288068-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | MMP9, MMP3, MMP12 | ADAM10 29/4885MMP2 23/4885ERBB2 2841/4885 |
| US-20140187530-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | ADAM10 29/4885MMP2 23/4885ERBB2 2841/4885 |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | MMP9, MMP25, HDAC5 | ADAM10 258/4885MMP2 41/4885ERBB2 2369/4885 |
| US-20070280943-A1 | SHEDDASE INHIBITORS COMBINED WITH CD30-BINDING IMMUNOTHERAPEUTICS FOR THE TREATMENT OF CD30 POSITIVE DISEASES | CD2, ENTPD1, PDCD10 | ADAM10 19/4885MMP2 1053/4885ERBB2 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.